Nachrichten und Videos - OXFORD BIOMEDICA ORD 50P - Seite 2

Oxford Biomedica plc Preliminary results for the year ended 31 December 202 1 Saving Lives Oxford, UK – 20 April 202 2 : Oxford Biomedica plc (LSE: OXB), (“Oxford Biomedica” or “the Group”), a leading cell and gene therapy group, today announces its preliminary results for the year ended 31 December 2021. Dr. Roch Doliveux , Chair and Interim Chief Executive Officer of Oxford Biomedica, said: “ I am delighted with our performance in 2021 which was a true testament to the hard work of...

Unique platform offering capabilities from vector design and process development through to clinical trials is now available to new customers Oxford, UK – 11 March 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or the “Company"), a leading gene and cell therapy group, is pleased to announce that it has completed its deal with Homology Medicines Inc. (Nasdaq: FIXX) (“Homology”), a genetic medicines company, to establish Oxford Biomedica Solutions LLC, a new US-based full scope,...

Oxford Biomedica announces that S io Gene Therapies intends to cease the license agreement for gene therapy programme in Parkinson’s disease N egligible financial impact on Oxford Biomedica in the short and medium term Non - core, legacy asset to be returned and out-licensed again in due course Oxford Biomedica fully focused as a global vector-agnostic gene and cell therapy innovative CDMO Oxford, UK – 3 1 January , 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"),...

Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines ’ established AAV capabilities in to a newly formed AAV Manufacturing and Innovation B usiness in the US with Homology Medicines as 20% owner Oxford Biomedica and Homology Medicines to establish Oxford Biomedica Solutions LLC , a new US - based AAV manufacturing and innovation business Homology Medicines to receive $130 million from Oxford Biomedica to continue to advance its three clinical program me...

Oxford Biomedica is a pioneer of gene and cell therapy with a leading position in lentiviral vector research and bioprocessing....

John Dawson to retire from Oxford Biomedica Oxford, UK – 17 January 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group” or “the Company”) a leading gene and cell therapy company, today announces that, after more than 13 years of service, John Dawson, Chief Executive Officer, has signalled to the Board his intention to retire from the Company. Accordingly, the Board has initiated a formal search for a successor. Dr. Roch Doliveux, Chairman of Oxford Biomedica,...

Oxford Biomedica A nnounces that Boehringer Ingelheim has E xercise d Option R elating to a Novel Gene Thera py Treatment for Cystic Fibrosis Oxford, UK – 19 October 2021: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, today announces that Boehringer Ingelheim has exercised its option to license Oxford Biomedica’s lentiviral vector technology to manufacture, register and commercialise BI 3720931, a lentiviral vector-based...

The information contained within thi s announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. Oxford Biomedica announces strategic investment by Serum Life Sciences Ltd Oxford,...

OXFORD BIOMEDICA PLC INTERIM RESULTS FOR T HE SIX MONTHS ENDED 30 JUNE 2021 Oxford Biomedica delivers record first half results Oxford, UK – 22 September 2 021 : Oxford Biomedica plc (“Oxford Biomedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group, today announces interim results for the six months ended 30 June 2021. John Dawson, Oxford Biomedica’s Chief Executive Officer, said: “Everyone at Oxford Biomedica can be truly proud of what they have continued to...

Edison Investment Research Limited Oxford Biomedica (OXB): Driving innovation in a thriving CGT industry 28-May-2021 / 07:00 GMT/BST London, UK, 28 May 2021 Oxford Biomedica (OXB): Driving innovation in a thriving CGT industry Oxford Biomedica (OXB) is one of few global lentiviral vector manufacturers with capacity in a thriving cell and gene therapy industry, and its FY20 results highlight strong operational progress throughout the business. OXB boasts a diversified revenue base; and FY20...

Edison Investment Research Limited Edison Investment Research Limited: Oxford Biomedica (OXB): Vector innovation key to cell and gene evolution 05-Oct-2020 / 10:59 GMT/BST London, UK, 5 October 2020 Oxford Biomedica (OXB): Vector innovation key to cell and gene evolution Oxford Biomedica (OXB) is a pioneer and global leader in the development and manufacture of commercial-scale lentiviral vectors (LVVs), a critical component of cell and gene therapies (CGTs). An investment in OXB gives a broad...

LONDON, UK / ACCESSWIRE / October 5, 2020 / Oxford Biomedica (OXB) is a pioneer and global leader in the development and manufacture of commercial-scale lentiviral vectors (LVVs), a critical component of cell and gene therapies (CGTs). An investment in OXB gives a broad exposure to this emergent industry. During the past 12 months, OXB has effectively doubled its CDMO partner programmes to 20, while broadening its own gene therapy R&D portfolio offering. Partner Axovant expects to report...

OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2019 Oxford, UK – 4 September 2019: Oxford Biomedica plc (“Oxford Biomedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group, today announces interim results for the six months ended 30 June 2019. FINANCIAL HIGHLIGHTS Revenues were £32.1 million, a decrease of 9% (H1 2018: £35.3 million) reflecting the significant licence income received in H1 2018. However, bioprocessing and commercial...

LONDON, UK / ACCESSWIRE / June 4, 2019 / Oxford Biomedica (LSE: OXB) is a pioneer and global leader in the development and manufacture of commercial-scale lentiviral vectors (LVV), a critical component of cell and gene therapies (CGT). OXB has numerous value streams, including manufacturing, royalties and milestones on partnered product sales. Its technology and R&D pipeline have been validated by numerous partnerships (Novartis's CAR-T Kymriah, Axovant deal for AXO-Lenti-PD). We believe the...

Oxford Biomedica notes the Japanese approval of Kymriah ® (tisagenlecleucel), the first CAR-T cell therapy authorised in Asia Oxford, UK – 26 March 2019: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, today notes an announcement by Novartis that Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved Kymriah ® (tisagenlecleucel) for the treatment of two distinct indications – CD19-positive relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia...

Oxford Biomedica plc Preliminary results for the year ended 31 December 2018 Delivery of dual strategy leads to strong financial growth Oxford, UK – 14 March 2019 : Oxford Biomedica plc (LSE: OXB), (“OXB” or “the Group”), a leading gene and cell therapy group today announces preliminary results for the year ended 31 December 2018. FINANCIAL HIGHLIGHTS Gross income increased by 72% to £67.9 million (2017: £39.4 million) Revenue increased by 78% to £66.8 million (2017: £37.6 million)...

Oxford BioMedica notes that Axovant doses first patient in clinical study of AXO-Lenti-PD, a novel gene therapy for patients with Parkinson’s disease Oxford, UK – 25 October 2018: Oxford BioMedica plc (LSE:OXB) (“Oxford BioMedica” or “the Group”), a leading gene and cell therapy group, notes that its partner, Axovant Sciences (NASDAQ:AXON), a company developing innovative gene therapies for neurologic and neuromuscular diseases, has announced the successful dosing of the first...

OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2018 Oxford, UK – 13 September 2018: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group, today announces interim results for the six months ended 30 June 2018. FINANCIAL HIGHLIGHTS Gross income growth of 118% to £36.0 million (H1 2017: £15.7 million) Operating EBITDA of £11.9 million compared to a loss of £2.1 million in H1 2017 Licence income of £18.3...

Oxford BioMedica announces further capacity expansion with new facility Lentiviral vector bioprocessing market expected to grow to $800m by 2026 Oxford BioMedica adds fourth facility in Oxford allowing the Group to target 25% to 30% of global lentiviral vector bioprocessing market (excluding milestones and royalties) Oxford, UK – 13 September 2018: Oxford BioMedica plc (LSE:OXB) (“Oxford BioMedica” or “the Group”), a leading gene and cell therapy group, today announces that it has...

Kymriah ® (tisagenlecleucel, formerly CTL019) receives European Commission Approval London, UK – 28 August 2018: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today notes that the European Commission (EC) has approved the Novartis CAR-T cell therapy, Kymriah ® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of paediatric and young adults up to 25 years of age with B-cell acute...